北米の医薬品添加剤市場 – 業界動向と2030年までの予測

北米の医薬品添加剤市場の分析と洞察

医薬品添加剤は、薬剤の処方と開発において重要な役割を果たします。これらの物質には、薬理学的に活性な薬物またはプロドラッグ以外の物質が含まれます。医薬品添加剤は、薬物を標的部位に効率的に送達します。これらの分子は、薬物が同化して薬効を高める際に、薬物が早期に放出されるのを防ぎます。一部の医薬品添加剤は、薬物の統合を促進し、血流中の薬物の吸収を高めます。

Data Bridge Market Research の分析によると、北米の医薬品添加剤市場は、予測期間中に 6.6% の CAGR で成長し、2030 年までに 68 億 9,431 万米ドルに達する見込みです。北米では IT ソリューションとサービスの需要が急増しているため、機能性が市場で最大のセグメントを占めています。この市場レポートでは、価格分析、特許分析、技術進歩についても詳細に取り上げています。

North America Pharmaceutical Excipients Market Definition

Pharmaceutical excipients involve everything in a drug except the active pharmaceutical ingredients. These molecules don’t possess medicinal properties and are ultimately used to enhance the drug's physiological absorption.  Pharmaceutical excipients are inert, allowing the drug molecule to apply to patients in the right form. Traditionally pharmaceutical excipients were simple molecules, but technological innovation and increasing demand for novel drug delivery systems enhanced the pharmaceutical excipient's complexity.  Pharmaceutical excipients promote the patient’s drug acceptability and boost the drug's stability and bioavailability.

The future of excipients science and technology has changed and continues to change. Better progress has been made in such areas as harmonizing excipient pharmacopeial monographs and applying new analytical methods to characterize excipients better.

North America Pharmaceutical Excipients Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail below:    

Drivers

• Rise in Generic Drug Production and Uses

According to the U.S. Food and Drug Administration (U.S. Food and Drug Administration). FDA) and the National Center for Biotechnology Information (NCBI), a generic drug is a drug that has been created to look like an approved brand-name drug that is available in dosage form, with safety, strength, route of administration, quality, and performance. After the drug's patent expires, the cost savings associated with conventional drug use are not immediately apparent. Generic drugs, like brand-name drugs, require competition in the generic drug market before reducing costs; two to three years after the loss of exclusivity, the price of a generic drug is usually 60-70% lower than that of a brand-name drug. Since India has the highest per capita spending, these generic drugs will save a lot of money that can be used for other health problems. Nationally, the use of generic drugs has increased significantly in recent years. The fact that cheap substitutes for branded drugs are a major reason likely to spur the growth of the pharmaceutical industry. The generic drug industry in the near future.

Thus, increasing demand for generic drugs and rising production are expected to drive the North America pharmaceutical excipients market growth. Also, the cost of generic drugs is less, which increases the use of generic drugs.

• The Surge in Demand for Excipients

Pharmaceutical excipients are substances in pharmaceutical dosage forms not for direct therapeutic use but to facilitate the manufacture, protection, support, or improvement of stability and availability. With the increased development of the North America pharmaceutical industry, excipients also have a light part. Recently, there has been an increasing demand for generic drugs, which has led to an increase in the excipients demand. In addition, there has been a sharp increase in cases of chronic diseases.

Excipients are inert substances, other than pharmaceutically active drugs, introduced into the manufacturing process or included in the dosage form of pharmaceutical products. Excipients are widely used in drug formulations to add bulk to solid formulations, provide long-term stability, and facilitate drug absorption. Furthermore, it also improves the product's overall safety or functional properties during use or storage.

Thus, wide uses of excipients in drug formulation and applications of excipients are expected to drive the North America pharmaceutical excipients market.

Restraint

• Increasing Regulatory Stringency Regarding The Approval of Drugs and Excipients

Generic drug approval rules are largely the same worldwide, with little difference in developing countries. This is because he is not required to undergo bioequivalence (BE) study in this part of the world to obtain generic drug approval. Governments must ensure consistent quality of all generic drugs, medical experts say. Only then will doctors be happy and confident in prescribing generic drugs. A major reason for physicians' (and even patients') lack of confidence in generic drugs has been the lack of strict regulatory requirements regarding the number of generic drugs and the number of impurities allowed.

Controlling the manufacture and distribution of excipients is now considered a top priority by regulators and drug manufacturers, as mixing excipients has resulted in adverse patient events. Furthermore, with the emergence of new excipients and delivery systems, better control of the quality and supply of pharmaceutical excipients has become increasingly important in the context of in vivo activity. Recognizing the important role of excipients in pharmaceutical dosage forms requires excipient suppliers to meet the quality requirements of the pharmaceutical industry, and the pharmaceutical industry, in general, must work to ensure the product's safety. The integrity of use or storage in the supply chain. Hence, the Increasing Regulatory Stringency Regarding the Approval of Drugs and Excipients is expected to restrain the North America pharmaceutical excipients market growth.

Opportunity

• Strategic Initiatives by Market Players

The rise in the pharmaceutical excipients market increases the need for strategic business ideas. It includes a partnership, business expansion, and other development. The rising demand for pharmaceuticals is significantly increasing the demand for pharmaceutical excipients, and to cope with this demand, companies are building new manufacturing sites, among other strategic initiatives.

These strategic initiatives, such as product launches, acquisitions, agreements, and business expansion by the major market player, will boost the pharmaceutical excipients market growth and are expected to act as an opportunity for the North America pharmaceutical excipients market.

Challenge

• Associated Side Effects

Adverse effects due to pharmaceutical excipients in drug formulations are generally uncommon, but the potential for toxicity is increased at high mg per kg doses, especially in neonates and infants. Methyl and Propyl para-hydroxybenzoate (Parabens), Benzyl Alcohol, Sodium Benzoate, Benzoic Acid, and Propylene Glycol, among others, are some of the common pharmaceutical excipients that have reported side effects.

Pharmaceutical excipients are not always the inert substances that we presume. They are intolerant to an individual or, if not properly screened, can cause chemical changes in the drug, causing the side-effect. This can affect the demand for the excipient and is expected to act as a challenge for the North America pharmaceutical excipients market.

Post-COVID-19 Impact on North America Pharmaceutical Excipients Market

The pharmaceutical industry has been severely affected by the COVID-19 pandemic. Lockdowns imposed due to the epidemic have disrupted the supply of raw materials from manufacturing centers such as India and China. This slowed drug development and production, severely affecting companies that relied heavily on outsourcing. Initially, the entire pharmaceutical ecosystem was disrupted. In addition, regulatory agencies had to draft and draft new laws to ensure maximum patient safety after using drugs. After the shutdowns ended, the pharmaceutical industry gained steam, especially due to the demand for drugs such as hydroxychloroquine and Remdesivir, which showed positive results against COVID-19. The growing demand for these drugs boosted the turnover of some companies.

Manufacturers are making various strategic decisions to bounce back post-COVID-19. The players are conducting multiple R&D activities, product launches, and strategic partnerships to improve the technology in the pharmaceutical excipients market.

Recent Developments

• In February 2022, Kerry Group Plc., the world’s leading taste and Nutrition Company, announced that it had made two significant biotechnology acquisitions that have expanded its expertise, technology portfolio, and manufacturing capabilities. The company has announced that it has acquired the leading biotechnology Innovation Company, c-LEcta, and Mexican-based enzyme manufacturer, Enmex. c-LEcta is a leading biotechnology innovation company specializing in precision fermentation, optimized bio-processing, and bio-transformation. Also, Enmex is a well-established enzyme manufacturer based in Mexico, supplying multiple bio-process solutions for food, beverage, and animal nutrition markets. This has helped the company to increase its revenue
• In September 2022, DFE Pharma, a North America leader in pharma- and nutraceutical excipient solutions, opened its new “Closer to the Formulator” (C2F), a Center of Excellence, in Hyderabad, India. C2F helped pharmaceutical companies to shorten the time from concept to finished commercial product through its expertise in all phases of pharmaceutical development. This has helped the company to showcase its progress

North America Pharmaceutical Excipients Market Scope

The North America pharmaceutical excipients market is segmented into functionality, dosage forms, route of administration, end-user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY FUNCTIONALITY

• Binders And Adhesives 
• Disintegrants 
• Coating Material 
• Coloring Agents
• Solubilizers
• Flavors
• Sweetening Agents
• Diluents
• Lubricants
• Buffers
• Emulsifying Agents
• Preservatives
• Antioxidants
• Sorbents
• Solvents
• Emollients
• Glidents
• Chelating Agents
• Antifoaming Agents
• Others

On the basis of functionality, the North America pharmaceutical excipients market is segmented into binders and adhesives, disintegrants, coating material, coloring agents, solubilizers, flavors, sweetening agents, diluents, lubricants, buffers, emulsifying agents, preservatives, antioxidants, sorbents, solvents, emollients, glidents, chelating agents, antifoaming agents, and others.

NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY DOSAGE FORM

• Solid
• Semi-Solid
• Liquid

On the basis of dosage forms, the North America pharmaceutical excipients market is segmented into solid, semi-solid, and liquid

NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY ROUTE OF ADMINISTRATION

• Oral Excipients 
•  Topical Excipients 
•  Parenteral Excipients 
•  Other Pharmaceutical Excipients 

On the basis of the route of administration, the North America pharmaceutical excipients market is segmented into oral pharmaceutical excipients, topical pharmaceutical excipients, parenteral pharmaceutical excipients, and other pharmaceutical excipients.

NORTH AMERICA PHARMACEUTICAL EXCIPIENTS MARKET, BY END-USER

• Pharmaceutical And Biopharmaceutical Companies
• 契約書作成者
• 研究機関と学術機関
• その他

エンドユーザーに基づいて、北米の医薬品添加剤市場は、製薬およびバイオ医薬品会社、契約製剤製造業者、研究機関および学術機関、その他に分類されます。

北米医薬品添加物市場（流通チャネル別）

• 直接入札
• 小売販売 
• その他 

流通チャネルに基づいて、北米の医薬品添加剤市場は、直接入札、小売販売、その他に分類されます。

北米医薬品添加剤市場の地域分析/洞察

北米の医薬品添加剤市場が分析され、機能性、剤形、投与経路、エンドユーザー、流通チャネルに関する市場規模の情報が提供されます。

この市場レポートで取り上げられている国は、米国、カナダ、メキシコです。

北米は、高い GDP を誇る最大の消費者市場に主要な市場プレーヤーが存在するため、優位に立っています。米国は、ヘルスケア IT の技術進歩の高まりにより、成長が見込まれています。

北米が市場を支配しています。研究開発への投資の増加により、市場の成長が促進されると予想されています。米国は、エボニック、ダウ、クローダ・インターナショナルなどの主要企業の強力な存在により、北米地域を支配しています。英国は、医薬品の大量生産、新興市場からの需要の増加、ヘルスケア産業の拡大により、ヨーロッパを支配しています。中国は、医薬品市場の急成長とジェネリック医薬品の生産の増加により、アジア太平洋地域を支配しています。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、国別データの予測分析を提供する際には、北米ブランドの存在と可用性、地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、販売チャネルの影響も考慮されます。

競争環境と北米の医薬品添加剤市場シェア分析

北米の医薬品添加剤市場の競争環境は、競合他社の詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と幅、アプリケーションの優位性、技術ライフライン曲線などがあります。提供されている上記のデータ ポイントは、北米の医薬品添加剤市場への会社の重点にのみ関連しています。

北米の医薬品添加剤市場で活動している主要企業としては、Kerry Group plc.、DFE Pharma、Cargill, Incorporated、Pfanstiehl、Colorcon、MEGGLE GmbH & Co. KG、Omya AG、Peter Greven GmbH & Co. KG、Ashland.、Evonik、Dow、Croda International Plc、Roquette Frères.、The Lubrizol Corporation、BASF SE、Avantor, Inc.、BENEO などがあります。

SKU-69288